{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:55:19Z","timestamp":1787028919048,"version":"build-2736575974"},"reference-count":23,"publisher":"MDPI AG","issue":"6","license":[{"start":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T00:00:00Z","timestamp":1781136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Medicina"],"abstract":"<jats:p>Background and Objectives: Surfactant protein B (SFTPB) is a surfactant-associated protein secreted by alveolar type II epithelial cells that plays a critical role in maintaining alveolar stability and surface tension. Although SFTPB is closely associated with pulmonary epithelial differentiation, its clinical significance in different non-small cell lung cancer (NSCLC) subtypes remains unclear. This study investigated the clinicopathologic and prognostic significance of SFTPB expression in lung adenocarcinoma (AD) and lung squamous cell carcinoma (SCC) using The Cancer Genome Atlas (TCGA) dataset. Materials and Methods: SFTPB mRNA expression data and clinicopathologic information were obtained from TCGA cohorts of AD and SCC patients. Patients were stratified into high- and low-expression groups according to median SFTPB expression levels. Associations between SFTPB expression and clinicopathologic variables were analyzed, and correlation analyses were performed with major oncogenic genes. Overall survival (OS) and relapse-free survival (RFS) were evaluated using Kaplan\u2013Meier survival analysis and log-rank testing. Multivariate Cox proportional hazards regression analyses were performed after adjustment for age, sex, and pathological stage. Results: In AD, high SFTPB expression was significantly associated with lower pathologic stage (p = 0.011) and lower N stage (p = 0.006). SFTPB expression showed significant negative correlations with EGFR (R = \u22120.140, p = 0.002) and BRAF (R = \u22120.177, p &lt; 0.001) and a positive correlation with TP53 (R = 0.128, p = 0.004). Patients with high SFTPB expression demonstrated significantly improved OS compared with those with low expression (p &lt; 0.001), while a trend toward prolonged RFS was observed without statistical significance (p = 0.089). Multivariate analysis confirmed high SFTPB expression as an independent favorable prognostic factor in AD (HR = 0.551, 95% CI = 0.405\u20130.748, p &lt; 0.001). In SCC, high SFTPB expression was also significantly associated with lower pathologic stage (p = 0.009) and lower N stage (p = 0.007). SFTPB expression showed significant negative correlations with SOX2 (R = \u22120.176, p &lt; 0.001), PIK3CA (R = \u22120.143, p = 0.002), and TP53 (R = \u22120.101, p = 0.026). In contrast to AD, high SFTPB expression was significantly associated with poorer OS (p = 0.026), whereas no significant difference in RFS was observed (p = 0.307). Multivariate analysis demonstrated that high SFTPB expression was an independent adverse prognostic factor in SCC (HR = 1.347, 95% CI = 1.028\u20131.767, p = 0.031). Conclusions: SFTPB expression is significantly associated with clinicopathologic characteristics and molecular signatures in both AD and SCC. However, its prognostic implications differ according to histologic subtype. High SFTPB expression independently predicts favorable survival in AD but unfavorable survival in SCC, suggesting distinct lineage-specific biological roles in NSCLC. These findings support SFTPB as a subtype-specific prognostic biomarker reflecting differential differentiation states and lineage context in NSCLC.<\/jats:p>","DOI":"10.3390\/medicina62061140","type":"journal-article","created":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T06:57:17Z","timestamp":1781161037000},"page":"1140","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["SFTPB Expression Predicts Favorable Survival in Lung Adenocarcinoma but Poor Prognosis in Lung Squamous Cell Carcinoma"],"prefix":"10.3390","volume":"62","author":[{"given":"Soonsoo","family":"Kim","sequence":"first","affiliation":[{"name":"Medical Course, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyowon","family":"Hong","sequence":"additional","affiliation":[{"name":"Department of Anatomy, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5562-0720","authenticated-orcid":false,"given":"Jae-Ho","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Anatomy, School of Medicine, Keimyung University, Daegu 42601, Republic of Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,11]]},"reference":[{"key":"ref_1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.pathol.2023.11.006","article-title":"Prognostic and Predictive Biomarkers in Non-Small Cell Lung Carcinoma","volume":"56","author":"Odintsov","year":"2024","journal-title":"Pathology"},{"key":"ref_3","unstructured":"WHO Classification of Tumours Editorial Board (2021). Thoracic Tumours, International Agency for Research on Cancer. [5th ed.]."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1056\/NEJMra0802714","article-title":"Lung Cancer","volume":"359","author":"Herbst","year":"2008","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1038\/nrc3775","article-title":"Non-Small-Cell Lung Cancers: A Heterogeneous Set of Diseases","volume":"14","author":"Chen","year":"2014","journal-title":"Nat. Rev. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.molmed.2019.04.012","article-title":"Abandoning the Notion of Non-Small Cell Lung Cancer","volume":"25","author":"Relli","year":"2019","journal-title":"Trends Mol. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"71759","DOI":"10.18632\/oncotarget.17606","article-title":"Eight Potential Biomarkers for Distinguishing between Lung Adenocarcinoma and Squamous Cell Carcinoma","volume":"8","author":"Xiao","year":"2017","journal-title":"Oncotarget"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1483","DOI":"10.3892\/mmr.2016.5420","article-title":"Identification of Differentially Expressed Genes between Lung Adenocarcinoma and Lung Squamous Cell Carcinoma by Gene Expression Profiling","volume":"14","author":"Lu","year":"2016","journal-title":"Mol. Med. Rep."},{"key":"ref_9","first-page":"1398","article-title":"Identification of Immunohistochemical Markers for Distinguishing Lung Adenocarcinoma from Squamous Cell Carcinoma","volume":"7","author":"Zhan","year":"2015","journal-title":"J. Thorac. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2014). Comprehensive Molecular Profiling of Lung Adenocarcinoma. Nature, 511, 543\u2013550.","DOI":"10.1038\/nature13385"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S1470-2045(10)70087-5","article-title":"New Driver Mutations in Non-Small-Cell Lung Cancer","volume":"12","author":"Pao","year":"2011","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1158\/2159-8290.CD-14-1236","article-title":"Co-Occurring Genomic Alterations Define Major Subsets of KRAS-Mutant Lung Adenocarcinoma with Distinct Biology, Immune Profiles, and Therapeutic Vulnerabilities","volume":"5","author":"Skoulidis","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cancer Genome Atlas Research Network (2012). Comprehensive Genomic Characterization of Squamous Cell Lung Cancers. Nature, 489, 519\u2013525.","DOI":"10.1038\/nature11404"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"17761","DOI":"10.1073\/pnas.1114669108","article-title":"Loss-of-Function Mutations in Notch Receptors in Cutaneous and Lung Squamous Cell Carcinoma","volume":"108","author":"Wang","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1056\/NEJMra022387","article-title":"Hydrophobic Surfactant Proteins in Lung Function and Disease","volume":"347","author":"Whitsett","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1097\/MOP.0000000000000751","article-title":"Genetic Causes of Surfactant Protein Abnormalities","volume":"31","author":"Nogee","year":"2019","journal-title":"Curr. Opin. Pediatr."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1513\/pats.201107-042ST","article-title":"International Association for the Study of Lung Cancer\/American Thoracic Society\/European Respiratory Society: International Multidisciplinary Classification of Lung Adenocarcinoma: Executive Summary","volume":"8","author":"Travis","year":"2011","journal-title":"Proc. Am. Thorac. Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S0167-4781(96)00180-7","article-title":"Regulation of Clara cell secretory protein gene transcription by thyroid transcription factor-1","volume":"1350","author":"Zhang","year":"1997","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_19","first-page":"1261","article-title":"Surfactant Protein B as a Differentiation Marker in Lung Adenocarcinoma","volume":"152","author":"Shijubo","year":"1995","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1146\/annurev.physiol.63.1.555","article-title":"Function of Surfactant Proteins B and C","volume":"63","author":"Weaver","year":"2001","journal-title":"Annu. Rev. Physiol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1146\/annurev.med.60.041807.123500","article-title":"Alveolar Surfactant Homeostasis and the Pathogenesis of Pulmonary Disease","volume":"61","author":"Whitsett","year":"2010","journal-title":"Annu. Rev. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/nrc2620","article-title":"Transitions between Epithelial and Mesenchymal States: Acquisition of Malignant and Stem Cell Traits","volume":"9","author":"Polyak","year":"2009","journal-title":"Nat. Rev. Cancer"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2131","article-title":"Snail, Zeb and bHLH Factors in Tumour Progression: An Alliance against the Epithelial Phenotype?","volume":"7","author":"Peinado","year":"2007","journal-title":"Nat. Rev. Cancer"}],"container-title":["Medicina"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T07:46:26Z","timestamp":1781163986000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1648-9144\/62\/6\/1140"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,11]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["medicina62061140"],"URL":"https:\/\/doi.org\/10.3390\/medicina62061140","relation":{},"ISSN":["1648-9144"],"issn-type":[{"value":"1648-9144","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,11]]}}}